Analysts Expect BioLife Solutions, Inc. (NASDAQ:BLFS) to Announce -$0.06 EPS

Equities analysts forecast that BioLife Solutions, Inc. (NASDAQ:BLFS) will post earnings of ($0.06) per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for BioLife Solutions’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.08). BioLife Solutions posted earnings of ($0.04) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The company is scheduled to report its next earnings report on Thursday, November 4th.

On average, analysts expect that BioLife Solutions will report full year earnings of $0.06 per share for the current year, with EPS estimates ranging from $0.03 to $0.09. For the next fiscal year, analysts forecast that the business will post earnings of $0.09 per share, with EPS estimates ranging from ($0.22) to $0.36. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Wednesday, August 11th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.15). The business had revenue of $31.20 million during the quarter, compared to analyst estimates of $28.32 million. BioLife Solutions had a net margin of 4.72% and a negative return on equity of 0.07%.

A number of equities research analysts recently weighed in on BLFS shares. KeyCorp lifted their target price on BioLife Solutions from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, August 13th. TheStreet upgraded shares of BioLife Solutions from a “d” rating to a “c” rating in a research note on Wednesday, September 1st. Zacks Investment Research upgraded shares of BioLife Solutions from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Northland Securities boosted their price objective on BioLife Solutions from $55.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, September 2nd. Finally, Cowen raised their price objective on shares of BioLife Solutions from $50.00 to $64.00 and gave the company an “outperform” rating in a research report on Friday, August 13th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions presently has a consensus rating of “Buy” and an average target price of $59.13.

In other BioLife Solutions news, VP Aby J. Mathew sold 8,854 shares of BioLife Solutions stock in a transaction dated Wednesday, July 21st. The shares were sold at an average price of $45.61, for a total value of $403,830.94. Following the completion of the sale, the vice president now owns 219,589 shares in the company, valued at approximately $10,015,454.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Aby J. Mathew sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 19th. The stock was sold at an average price of $43.85, for a total transaction of $438,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 233,282 shares of company stock worth $10,832,983. Corporate insiders own 5.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Louisiana State Employees Retirement System acquired a new position in BioLife Solutions during the third quarter valued at approximately $592,000. State of Alaska Department of Revenue acquired a new position in BioLife Solutions during the third quarter valued at approximately $897,000. Morgan Stanley raised its position in BioLife Solutions by 81.5% during the second quarter. Morgan Stanley now owns 88,676 shares of the medical equipment provider’s stock valued at $3,946,000 after purchasing an additional 39,823 shares in the last quarter. Invesco Ltd. raised its position in BioLife Solutions by 17.8% during the second quarter. Invesco Ltd. now owns 494,461 shares of the medical equipment provider’s stock valued at $22,009,000 after purchasing an additional 74,816 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY raised its position in BioLife Solutions by 174,050.0% during the second quarter. Metropolitan Life Insurance Co NY now owns 6,966 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 6,962 shares in the last quarter. Institutional investors and hedge funds own 68.31% of the company’s stock.

BLFS stock traded up $1.28 during trading on Friday, reaching $40.15. 6,845 shares of the stock were exchanged, compared to its average volume of 341,696. BioLife Solutions has a twelve month low of $26.58 and a twelve month high of $60.67. The company has a market capitalization of $1.63 billion, a P/E ratio of 647.94, a price-to-earnings-growth ratio of 91.16 and a beta of 1.42. The stock has a 50 day simple moving average of $47.60 and a 200-day simple moving average of $41.51. The company has a current ratio of 4.07, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01.

About BioLife Solutions

BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.

See Also: What is the yield curve?

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.